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CObjective: Assessment of the effectiveness compared with alternative
treatment(s) plays an important role inmany jurisdictions in determin-
ing the reimbursement status of pharmaceuticals. This type of assess-
ment is often referred to as a relative effectiveness assessment (REA)
and is carried out by many jurisdictions. Increased sharing of informa-
tion across jurisdictions may save costs and reduce duplication. The
objective of this study was to explore the main similarities and differ-
ences in the major methodological aspects of REA in multiple
jurisdictions. Methods: Data were gathered with a standardized data
extraction form by searching publicly available information and by
eliciting information from representatives at relevant organizations.
Results: Of the initially included 35 jurisdictions, data were gathered for
29 jurisdictions. There seem to be substantial similarities on the choice of
the comparator, the role of indirect comparisons, and preferred end
points in REAs (except for the use of health state utilities). Jurisdictions, O
zeke
al So
ttp://dx.doi.org/10.1016/j.jval.2012.04.010owever, differ in whether effectiveness (usual circumstances of health
are practice) is estimated in case no (comparative) effectiveness data are
vailable and how this is done. Conclusion: Some important method-
logical aspects for REA are approached in a similar way inmany juris-
ictions, indicating that collaboration on assessmentsmay be feasible.
nhanced collaboration in the development of methods and best prac-
ices for REA between jurisdictionswill be a necessary first step. Impor-
ant topics for developing best practice are indirect comparisons and
ow to handle the gap between efficacy and effectiveness data in case
ood quality comparative effectiveness data are not yet available at the
ime of reimbursement decisions.
eywords: comparative effectiveness, health technology assessment,
harmaceuticals, policy, reimbursement.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Funding or reimbursement of a pharmaceutical by the health ser-
vice or health insurance is one of the factors that determine timely
access for patient to the pharmaceutical. The decision onwhether
a pharmaceutical is reimbursed is based on multiple factors. The
efficacy and/or effectiveness compared with alternative interven-
tions is typically considered one of the most important criteria in
determining reimbursement status [1]. This type of assessment is
often referred to as a relative efficacy/effectiveness assessment
(REA) (for definition used in this article, see Fig. 1) [2–4]. An REA is
a specific element of health technology assessment (HTA) that
focuses on the clinical benefit of the intervention, whereas HTA is
broader and can also include other aspects, such as ethical, cost,
and cost-effectiveness considerations.
There are two types of REA, a rapid assessment and a full as-
sessment. A rapid assessment is an assessment of one pharma-
ceutical within a limited time frame in comparison with one or
more relevant alternative interventions. It can be the assessment
of a new pharmaceutical launched into the market, or the (re)as-
* Address correspondence to: Sarah Kleijnen, College voor zorgver
E-mail: skleijnen@cvz.nl.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.sessment of a pharmaceutical for a new indication or when new
relevant data are available. For a full assessment, multiple tech-
nologies within a disease area are assessed. The latter type of
assessment is typically conducted several years after the technol-
ogies have been introduced to the market. Such an assessment
may not have to be carried out within a certain time frame. This
analysis focuses on rapid assessments.
While there is general consensus that the decision-making
process on reimbursement decisions should be undertakenwithin
national and local contexts, there are potential efficiencies to be
gained from enhanced collaboration around the collection of evi-
dence underpinning these decisions. Increased sharing of infor-
mation (e.g., methods, data requirements, and results) across ju-
risdictions may save costs and reduce duplication. A working
group of the High Level Pharmaceutical Forum, a high-level polit-
ical platform, was set up to support member states of the Euro-
pean Union in applying REAs in order to allow containment of
pharmaceutical costs as well as a fair reward for innovation. After
the completion of the High Level Pharmaceutical Forum 2005–
2008, the European Network for Health Technology Assessment
ringen, PO Box 80082, 3508 TB Diemen, The Netherlands.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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955V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 5 4 – 9 6 0(EUnetHTA) was identified as an appropriate candidate for develop-
ngscientific recommendations for improvements inREAofpharma-
euticals in Europe. The overarching objective of EUnetHTA Joint Ac-
ion is to put into practice an effective and sustainable HTA
ollaboration in Europe that brings added value at the European, na-
ional, and regional levels.
As a first step, an analysis was conducted of the arrangements
and the scientific methods used for REA in current national prac-
tice. The objective of this study was to explore the main similari-
ties and differences in themajormethodological aspects of REA in
multiple jurisdictions: the choice of comparator, the use of indi-
rect comparisons, the use of outcome measures, and the use of
efficacy data for effectiveness assessments.
Methods
Data were captured with a standardized data extraction form de-
veloped by seven EUnetHTA partners (AETSA [ES], AHTAPol [PO],
CVZ [NL], HAS [FR], ESKI [HU], IRF [DE], and the National Institute
forHealth andClinical Excellence [UK]) that conductHTAs of phar-
maceuticals. The form included 38 open or multiple-choice ques-
tions (the multiple-choice questions were to be answered with
yes/no or always/sometimes/never). Data were gathered by
searching publicly available information and by eliciting informa-
tion from representatives at relevant organizations (see Fig. 2). The
answers were checked by the researchers for inconsistencies and
clarity, and if neededwere queried. Defining or exploring the exact
meaning of the term “relative effectiveness” was not the purpose
of this work. As a result, terms such as “relative effectiveness as-
sessment” were not specifically defined in the data extraction
form. The responses received therefore reflect the individual re-
spondents’ understanding of the term.
Originally, we included 31 European jurisdictions and four
English-speaking non-European jurisdictions, most of which are
known to have a well-established HTA process for pharmaceuti-
cals (Canada, Australia, and New Zealand) or is known for its in-
terest in REA (the United States).
For each jurisdiction, in particular, the major methodologi-
cal aspects of the “comparative analysis” were collected. The
comparative analysis refers to assessing the efficacy and/or ef-
fectiveness of pharmaceutical(s) in comparison to alternatives.
Relevant definitions that were used are provided in Figure 1
[2,5,6]. The results were double-checked by representatives of
the respective organizations.
Relative efficacy: the extent to which an interventio
circumstances, compared to one or more alternative
Relative effectiveness: the extent to which an inte
or more intervention alternatives for achieving the d
circumstances of health care practice [2] 
Surrogate endpoint: a laboratory measurement or
meaningful endpoint that measures directly how a p
Composite endpoint: An endpoint that consists of
outcome measure by using a predefined algorithm [
Health state utility: value assigned to the quality o
to 1 (full health) 
Fig. 1 –Data were gathered between May 1, 2010, and May 1, 2011.Results
Of the originally included 35 jurisdictions, data were gathered for
29 jurisdictions (Australia, Austria, Belgium, Canada, the Czech
Republic, Denmark, Estonia, Finland, France, Germany, Hungary,
Ireland, Italy, Latvia, Luxembourg, Malta, the Netherlands, New
es more good than harm under ideal 
rventions [2] 
on does more good than harm compared to one 
d results when provided under the usual 
sical sign used as a substitute for a clinically 
t feels, functions or survives [5] 
ple endpoints that are combined into a new single 
n a health state, normally on a scale of 0 (dead) 
itions.
38 questions in 4 sections: 
Section A: Health care system 
Section B: General section on 
pharmaceuticals 
Section C: methodological 
aspects of a REA of 
pharmaceuticals as part of a 
rapid assessment 
Section D: methodological 
aspects of a REA of 
pharmaceuticals as part of a full 
assessment 
Data were abstracted from different types of literature (peer 
reviewed, grey literature, EU and national reports) 
Results were double-checked†
Step 1 
Step 2 
Step 3 
Data abstraction process per jurisdiction 
Data gathered 
Data presented in this article: 
Methodological aspects of a 
relative effectiveness 
assessment:  
 the choice of comparator 
 the use of indirect 
comparisons 
 the use of outcome 
measures 
 use of efficacy/effectiveness 
data 
 availability of guideline 
Results were complemented by eliciting information from 
representatives of institutions that are directly involved in 
the reimbursement process* 
■
■
■
■
■
Fig. 2 – Methods. *A semistructured questionnaire that
focused on information unavailable in the literature was
administered. The questions were either mailed and filled in
independently by the expert or administered through a
telephone interview. In both cases, the answers were checked
by the researchers for inconsistencies and clarity and
challenged if needed by asking queries. †The results were
double-checked by representatives from the respectiven do
 inte
rventi
esire
 a phy
atien
 multi
6] 
f life iinstitutions.
f956 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 5 4 – 9 6 0Zealand, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Swe-
den, Switzerland, Turkey, and the United Kingdom [separate data
extraction for England/Wales and Scotland]). Data were not avail-
able for Bulgaria, Cyprus, Greece, Lithuania, andRomania, because
no suitable sources for these jurisdictions were identified. No data
were collected for the United States, given that there is no single
entity or standardized approach for REA in the United States be-
cause of its multipayer environment [7,8].
The organizations that were selected for eliciting information
or each jurisdiction are listed in Appendix 1 at Supplemental Ma-
terials found at http://dx.doi.org/10.1016/j.jval.2012.04.010.
For the United Kingdom, separate data were abstracted of the
methods used by the National Institute for Health and Clinical
Excellence and the Scottish Medicines Consortium, as both have
well-established procedures and methods.
Of the jurisdictions included, all conduct rapid assessments
whereas 17 jurisdictions conduct full assessments. The results
presented in this article are specific to rapid assessments.
As part of a rapid assessment, relative efficacy was stated to be
assessed in all jurisdictions (83% state to do so always and 17%
sometimes).More than 95%of the jurisdictions state that they look
at the relative effectiveness (41% always and 55% sometimes). It
was stated by some of the jurisdictions that effectiveness is as-
sessed only when direct data on this parameter are available,
whereas other jurisdictions estimate the effectiveness if the data
are not available. In addition, more than 95% include a cost-effec-
tiveness assessment (62% sometimes and 34% always).
Choice of comparator
In many jurisdictions, several options can exist for the choice of
comparator. For example, in Poland, the primary comparator for
the assessed intervention must be the so-called existing practice.
It is also recommended, however, to perform a comparison with
other comparators (the most frequently used, the cheapest, the
most efficient, and compliant with the standards and guidelines
for clinical management). Only five jurisdictions (almost 20%)
state that “whatever was used in the registration trials” can be an
option for the choice of the comparator (Belgium, Slovakia, Slove-
nia, Spain, and Switzerland) (see Table 1). The majority (almost
70%) of the jurisdictions state “best standard care” and/or “other”
(almost 50%) as an option for the choice of comparator. The juris-
dictions were asked for their definition of the choice of compara-
tor. For both categories (“best standard care” and “other”), the def-
initions that jurisdictions use are similar. Examples of definitions
are “the treatment(s) used in current clinical practice” (England/
Wales), “most frequently (or widely) used therapy” (Belgium, Esto-
nia, Finland, and Latvia), “the validated care in the field” (France),
and “the therapy that prescribers would most replace with the
proposed pharmaceutical in practice” (Australia).
In 83% of the jurisdictions, the comparator(s) for the assess-
ment can include one or more nonpharmaceutical interventions.
In practice, however, the comparison with nonpharmaceuticals is
an exception in some of these jurisdictions. It was alsomentioned
that for pharmaceuticals used in an inpatient setting than in the
outpatient setting it is more common to include nonpharmaco-
logical interventions. The comparator is limited to pharmaceuti-
cals in Belgium, Canada, Denmark, Italy, and Norway.
Indirect comparison
When there are no head-to-head trials available that include a
direct comparison between the pharmaceutical to be assessed and
the relevant comparator, all jurisdictions, except for Turkey, may
use indirect comparisons (see Table 1). Only few jurisdictions state
to have a preference for the type of indirect analysis; for example,
Australia and New Zealand indicated a preference for the Fre-
quentist method and in Scotland, Bayesian analysis is preferred.Outcomes
In general, all clinically relevant outcomes are accepted for the
assessment. Several jurisdictions prefer outcomes related to mor-
tality, morbidity, and/or quality of life. Final outcomes (preferably
patient-relevant and clinically significant end points) are pre-
ferred over surrogate end points by all jurisdictions. The results on
individual end points are presented in Table 1 and Figure 3.
In all jurisdictions, surrogate outcomes are accepted for the
assessment. However, many jurisdictions state that surrogate
outcomes are not preferred, considered less relevant for the deci-
sion making than clinical outcomes, and are accepted only if con-
sidered clinically relevant and/or validated. Composite outcomes
are also generally accepted but not preferred.
Most jurisdictions accept quality-of-life data with the premise
that the instrument used should be validated. Disease-specific
quality-of-life measurements are accepted slightly more widely
(90%) than generic quality-of-life measurements (almost 80%). Al-
most half of the jurisdictions (48%) state that health state utilities
can be used for determining the relative effectiveness.
Almost all jurisdictions take safety data into account for the
assessment. Various outcomes such as dropout from study due to
side effects, deaths due to side effects, major side effects, and
irreversible side effects were mentioned as particularly relevant
safety end points.
Efficacy versus effectiveness data
All jurisdictions consider to some degree (“always” or “some-
times”) whether clinical trial data available at the time of the as-
sessment are also applicable to the general patient population
(also referred to as external validity) (Table 1). The organizations
were asked how effectiveness is assessed if no effectiveness data
from clinical studies are available. They were asked whether they
would do always/sometimes/never 1) a qualitative extrapolation
(estimate of the effectiveness of a treatment basedon the efficacy
data that are available) or 2) a quantitative extrapolation (e.g.,
modeling). A qualitative extrapolation is done at least sometimes
by 75% of the organizations. A quantitative exercise to extrapolate
efficacy data to effectiveness data is done at least sometimes by
50% of the organizations (Table 1). In the absence of long-term
data, short-term data are extrapolated qualitatively in almost 70%
of the jurisdictions (always or sometimes) and quantitatively
(throughmodeling) inmore than 60% (always or sometimes) of the
jurisdictions.
Methodological guidelines
More than 80% of the jurisdictions state that some form of guide-
line is available in which the methodology that is used for the
comparative analysis is described. Of the countries that have such
national guidelines, more than 60% indicate to have it available in
English. The methodological guidelines are publicly available in
most jurisdictions. The guidelines vary substantially across coun-
tries in the type of content (methods vs. other information regard-
ing procedure of reimbursement submission) aswell as the level of
detail on methods (evidence and methodological requirements).
Some of the national guideline documents focus mainly on the
procedure of a reimbursement submission (how to do a submis-
sion and the timelines involved) or, for example, on which reim-
bursement criteria are used for the assessment. The information
in these guidelines on how to perform/assess the REA can be lim-
ited. Other jurisdictions, such as the Czech Republic and Portugal,
use the national guideline for pharmacoeconomics as guidance to
inform the REA. An example of a detailed guideline on the meth-
ods used to perform/assess the REA is Section B of the guidelines of
the Australian Pharmaceutical Benefits Advisory Committee. This
guideline focuses on howmarketing authorization holders should
perform an REA and present the data [9].
Table 1 – Results.
Jurisdiction Comparator/comparison Outcomes Efficacy vs. effectiveness Guidelines
With what is the
pharmaceutical
compared?
Is comparison
limited to
pharmaceuticals?
If there are no direct
comparisons, are
indirect
comparisons
used in the REA?
Are
surrogate
end points
included?
Are composite
end points
included?
Are generic
quality-of- life
end points
included?
Are
utilities
used?
Are disease-specific
quality-of-life
end points
included?
Are safety
data taken
into
account?
Is the generalizability
of the study data
(e.g., RCTs) to
the proposed
treatment
population
considered
(external validity)?
How is the effectiveness
assessed if not available
through clinical trial data?
If data on long-term effects
are absent, are short-term
clinical data extrapolated?
Are there
guidelines for
conducting
REA?
Qualitative
description
based on
efficacy
data
Quantitative
extrapolation
(e.g., modeling)
of efficacy data
No
extrapolation
Qualitative
description
based
on short-term
data
Quantitative
extrapolation
(e.g., modeling)
of short-term
data
AU O N Y Y Y Y Y Y Y A S S S S S Y
AT O N Y Y Y Y N Y Y A S NE A NE NE Y
BE R, O Y Y Y Y Y N Y Y A A NE NE A NE N
CA O Y Y Y Y Y Y Y Y A A A S S S Y
CZ O N Y Y Y Y Y Y Y S S S S NE S Y
DK O Y Y Y Y N N Y Y A S NE S S NE Y
EN/WA BS N Y Y Y Y Y Y Y A A A NE A A Y
EE BS N Y Y Y Y Y Y Y A S NE S S S Y
FI BS N Y Y Y Y Y Y Y A S NE S S S N
FR BS N Y Y Y Y N Y Y A A NE A NE NE N
GE BS N Y Y Y Y N Y Y A NE NE A NE NE Y
HU BS N Y Y Y Y Y Y Y S NE NE S S S Y
IE BS N Y Y Y Y Y Y Y A S S S S S Y
IT BS Y Y Y Y N N Y Y S NE NE A NE NE Y
LA BS, O N Y Y Y N N N Y A S S S S S Y
LU O N Y Y Y N N N Y S A NE NE A NE N
MA BP, BS, O N Y Y M M N Y Y S S NE A NE NE Y
NL BS N Y Y Y Y N Y Y A S NE S S NE Y
NZ BS N Y Y Y Y Y Y Y A S S S S S Y
NO O Y Y Y Y Y Y Y N S NE S NE NE S Y
PL BP, BS, O N Y Y Y Y Y Y Y A S S S S S Y
PT BP, BS N Y Y Y Y N Y Y A A S S S S Y
SC O N Y Y Y Y N Y Y A A S NE S S Y
SK R, BP, BS N Y Y Y Y Y Y Y A NE NE S S S Y
SI R, BP, BS N Y Y Y Y Y Y Y S S S S S S Y
ES R, BP, BS, O N Y Y Y Y N Y Y S M M A NE NE Y
SE BS, O N Y Y Y Y Y Y Y A NE A NE NE A Y
CH R, BP, BS N Y Y Y Y N Y Y S NE NE S S NE Y
TU BS N N Y Y N N N Y S S A NE S A N
Percentage
(%)
R  17 Y  17 Y  97 Y  100 Y  97 Y  79 Y  48 Y  90 Y  97 A  66 A  25 A 14 A  21 A  10 A  10 Y  83
BP  24 N  83 N  3 N  0 N 0 N 17 N  52 N  10 N  3 S 34 S  50 S 36 S  55 S  59 S  52 N  17
BS  69 NE  0 NE  25 NE 50 NE  24 NE  31 NE  38
O  48
A, always; AU, Australia; AT, Austria; BE, Belgium; BP, best possible care; BS, best standard care; CA, Canada; CZ, Czech Republic; DK, Denmark; EN/WA, England/Wales; EE, Estonia; FI, Finland; FR,
France; GE, Germany; HU, Hungary; IE, Ireland; IT, Italy; LA, Latvia; LU, Luxembourg; M, data are missing; MA, Malta; N, no; NE, never; NL, Netherlands; NZ, New Zealand; NO, Norway; O, other;
PL, Poland; PT, Portugal; R, whatever is used in registration trials; RCTs, randomized controlled trials; REA, relative effectiveness assessment; S, sometimes; SC, Scotland; SK, Slovakia; SI, Slovania:
ES, Spain; SE, Sweden; CH, Switzerland; TU, Turkey; Y, yes.
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958 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 5 4 – 9 6 0Discussion
This article presents an overview of the similarities and differ-
ences in the main methodological aspects of REA of pharmaceuti-
cals between 29 jurisdictions. This is the largest number of juris-
dictions studied in this degree of detail for this purpose. Previously
published similar comparisons were limited to three to six coun-
tries and focused on the scope and/or process for the assessment
of pharmaceutical(s) [1,7,8,10–12].
Although the precise wording of the definitions of the relevant
comparator varies across jurisdictions, the meaning and what is
understood as a comparator is very similar; in most jurisdictions,
the relevant comparator is understood to be “usual care.” In an
analysis by Sorenson et al. [1], it is referred to as routine treatment.
In the majority of jurisdictions analyzed in the current article, the
choice of the comparator is not limited to pharmaceuticals. In
addition, direct comparisons are preferred; however, indirect
comparisons are usually accepted if no direct comparisons are
available.
Similar to the results of Sorenson et al. [1], the outcomes mor-
ality, morbidity, and quality of life were mentioned as preferred
utcomes by various jurisdictions.. Our findings confirm the re-
sults of Levy et al. [8] regarding surrogate outcomes; these are
generally not preferred, but accepted under certain circumstances
(if considered clinically relevant and/or validated). Most jurisdic-
tions include quality-of-life data with the premise that the instru-
ment used should be validated; however, health state utilities are
not used uniformly across jurisdictions. Although most countries
are interested in the relative effectiveness, effectiveness data are
often not available around the time of market authorization of a
newpharmaceutical. Our data show that in such cases some coun-
tries limit their assessment to relative efficacy. Themajority of the
jurisdictions, however, sometimes or always attempt to extrapo-
late effectiveness data from randomized controlled trials to daily
clinical practice. In some countries, they refer to a qualitative ex-
trapolation, which is an interpretation (estimate) of the effective-
ness of a treatment based on the efficacy data that are available.
Some jurisdictions use modeling exercises to extrapolate efficacy
data. This does not seem to be common practice in themajority of
European jurisdictions and is probablymostly done in countries in
which modeling is carried out for a cost-effectiveness or cost-util-
ity assessment.
On the basis of these findings, we conclude that there aremore
similarities than differences between the major methodological
aspects used in the jurisdictions. There seems to be substantial
similarities regarding the choice of the comparator and preferred
end points, except for the use of health state utilities in REAs.
However, there is more divergence in whether effectiveness is
assessed and whether effectiveness is estimated if no effective-
Safety data taken into account?
DSQoL endpoints included?
Health state utilities included?
GQoL endpoints included?
Composite endpoints included?
Surrogate endpoints included?
Fig. 3 – Jurisdictions that accept/include specific outcomes (i
quality of life; GQOL, generic quality-of-life data.ness data are available. Our conclusion is also supported by resultsof other studies. Levy et al. [8] concluded for Australia, Canada,
Netherlands, Scotland, and Sweden that the same type of data are
evaluated with a preference for head-to-head comparisons and
trials that approximate routine clinical practice as much as possi-
ble. Clement et al. [10] concluded that differences in reimburse-
ment decisions resulted less often from the interpretation of the
clinical or economic evidence andmore from differences between
processes used by different organizations. A less recent compari-
son between 12 countries regarding comparative evaluations of
pharmaceuticals also found many similarities between these
countries, but the authors also concluded that international
agreed standards for doing assessments are lacking [13].
The research methods used in this study have some limita-
tions. The results addressed in this article were gathered by elic-
iting information from representatives at relevant organizations.
A lack of standardization of terms may have led to differences in
the individuals’ interpretation of the terms. Some representatives
completed the survey by themselves, whereas others were inter-
viewed by telephone. Because of the size of the study, it was not
possible to use one singlemethod for eliciting the information.We
have, however, minimized difference in interpretation by the rep-
resentatives by cross-checking the results for inconsistencies,
challenging these, and asking queries. In addition, final results
from literature and interviews were validated by the interviewees
or colleagues from the same institution.
Under ideal circumstances the comparator for an assessment
that is shared across jurisdictions would be the reference treat-
ment according to clinical practice guidelines at European or in-
ternational level with good quality evidence on effect size and
adverse effects from scientific literature, and with a European
Union marketing authorization for the respective indication and
line of treatment. If such reference treatment, however, does not
exist and usual care differs between jurisdictions, sharing of infor-
mation on assessments across jurisdictions is challenging and in-
dustry have to prepare submission files for different jurisdictions
with different comparators. Clinical practice patterns can vary be-
tween jurisdictions because they are defined by a number of fac-
tors, including organization of the health care system, availability
of resources, and economic patterns [4]. Nevertheless, in most
assessments in various jurisdictions, the same pivotal trials are
used, indicating that the same comparator is used in these juris-
dictions. Where care patterns differ between jurisdictions, direct
and indirect comparisons may be used to include all context-rel-
evant comparisons. In addition, as Jönsson [4] pointed out, varia-
tion in usual caremay diminish over time because of convergence
of patterns of clinical practice and an increase in evidence-based
decision making.
The aim of REA is to compare health care interventions in daily
practice on the basis of the synthesis of available evidence. Al-
97%
90%
48%
79%
97%
100%
ilable) for the assessment (%). DSQOL, Disease-specificf avathough data from comparative studies (direct comparisons) are
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959V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 5 4 – 9 6 0mostly preferred, for a considerable number of pharmaceuticals
such data are not available around the time of marketing authori-
zation because no active control study was performed or the re-
sults are not published [14,15]. In addition, surrogates are often the
main end points in the clinical studies that form the basis for the
reimbursement submission [10], indicating that trials are not ideal
for reimbursement decision making. Decision makers struggle
with the challenge associated with the limited availability of or
quality of the evidence [7]. Clement et al. [10] identified significant
uncertainty around clinical effectiveness as a key issue in reim-
bursement decisions. The increased interest in comparative effec-
tiveness data worldwide and increased resources for conducting
these type of studies, through, for example, The American Recov-
ery and Reinvestment Act of 2009 [16], may boost the amount and
quality of effectiveness data that will be available in the future
[17,18]. This will result in a better understanding of the effective-
ness of pharmaceuticals in clinical practice and will improve the
ability tomake evidence-based decisions for individual patients as
well as for the development of national recommendations.
Partly to address the problem of limited evidence, some juris-
dictions are exploring the use of conditional reimbursement or
coverage with evidence development [7]. However, even such an
approach has to be based on the available evidence at the time.
Hence, an REA shortly after market authorization often has to
include an estimate of how efficacy data in experimental studies
can predict (comparative) effectiveness in clinical practice. There-
fore, indirect comparisons currently play an important role in the
REA of pharmaceuticals directly after market authorization. The
use of indirect comparisons for evaluating health care interven-
tions has been studied in detail [19–22]. So far, however, relatively
few jurisdictions provide clear guidance on which techniques are
preferred for REA [23,24]. There is a clear need for internationally
agreed guidelines in this area. In addition, harmonization and/or
standardization in the approaches how to extrapolate from effi-
cacy to effectiveness datawould also be an important step to shar-
ing assessments. Although not applicable to all countries, our
findings confirm the finding by Zentner et al. [13] that methodol-
gies for REA are less well described than pharmacoeconomic
ethodologies or other drug evaluation aspects. Hence, there is
need for detailed guidelines on methodological requirements
or REAs.
This article specifically focuses on the methods for an REA.
lthough a very relevant step, harmonization ofmethods and best
ractices for REA between jurisdictions is not identical to harmo-
ization of market access in various jurisdictions. The reimburse-
ent decision-making process is a national/regional responsibil-
ty. Other criteria such as cost-effectiveness and budget impact
an be relevant for the decision, and differences in the process of
eimbursement evaluations can lead to variance in the timing of
arket access. Even more, jurisdictions can make different reim-
ursement decisions on the basis of the outcome of the same REA
f there is difference in perception of the value of the available
ata, for example, for cultural reasons. One jurisdictionmay value
mprovement of progression-free survival as clinically relevant,
hile another jurisdiction may not find this sufficient and require
ata on overall survival. Furthermore, one jurisdiction may be
illing to accept a higher level of uncertainty than the other. Nev-
rtheless, this does not diminish the benefits of harmonizing REA
s this harmonization has the potential to lead to efficiency gains
or assessment agencies as well as industry, which in the endmay
ead to faster access for patients to new pharmaceuticals.
REA has attained an increasing role in reimbursement deci-
ions of pharmaceuticals. Not only does it contribute to evidence-
ased clinical decision making, it also forms an integral part in
dentifying the pharmaceuticals that offer the most value for
oney [1]. Enhanced collaboration and development of methodsnd best practices for REA between jurisdictions may improve ef-
ciency in the assessment of health technologies [1,3,4].
Conclusion
The results presented in this article show that some important
methodological aspects for REA are approached in a similar way
in many jurisdictions, indicating that collaboration on assess-
ments may be feasible. Enhanced collaboration in the develop-
ment of methods and best practices for REA between jurisdictions
will be a necessary first step. Important topics for developing best
practices are indirect comparisons and how to handle the gap
between efficacy and effectiveness data in case no good quality
comparative effectiveness data are available at the time of reim-
bursement decisions.
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